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Cell secretion is an important physiological process that ensures smooth metabolic activi-
ties and tissue repair as well as growth and immunological functions in the body. Apocrine
secretion occurswhen the secretory process is accomplishedwith a partial loss of cell cyto-
plasm. The secretory materials are contained within secretory vesicles and are released
during secretion as cytoplasmic fragments into the glandular lumen or interstitial space.The
recent ﬁnding that the non-synonymous single nucleotide polymorphisms (SNP) 538G > A
(rs17822931; Gly180Arg) in the ABCC11 gene determines the type of earwax in humans
has shed light on the novel function of this ABC (ATP-binding cassette) transporter in apoc-
rine glands.The wild-type (Gly180) of ABCC11 is associated with wet-type earwax, axillary
osmidrosis, and colostrum secretion from the mammary gland as well as the potential risk
of mastopathy. Furthermore, the SNP (538G > A) in the ABCC11 gene is suggested to be
a clinical biomarker for the prediction of chemotherapeutic efﬁcacy. The aim of this review
article is to provide an overview on the discovery and characterization of genetic polymor-
phisms in the human ABCC11 gene and to explain the impact of ABCC11 538G > A on the
apocrine phenotype as well as the anthropological aspect of this SNP in the ABCC11 gene
and patients’ response to nucleoside-based chemotherapy.
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INTRODUCTION
ATP-binding cassette (ABC) proteins form one of the largest pro-
tein families encoded in the human genome (Dean et al., 2001;
Holland et al., 2003). Hitherto more than 48 human ABC protein
genes have been identiﬁed and sequenced (Klein et al., 1999). It has
been reported that mutations of ABC protein genes are causative
of several genetic disorders in humans (Dean et al., 2001). Many
of the human ABC proteins are involved in membrane transport
of drugs, xenobiotics, endogenous substances, or ions, thereby
exhibiting a wide spectrum of biological functions (Schinkel and
Jonker, 2003). Based on the arrangement of molecular structure
components, i.e., nucleotide binding domains and topologies of
transmembrane domains, the hitherto reported human ABC pro-
teins have been classiﬁed into seven different sub-families (A to G;
Klein et al., 1999; Borst and Elferink, 2002; Ishikawa, 2003).
In 2001, three research groups independently cloned two novel
ABC transporters named ABCC11 and ABCC12 from the cDNA
library of human adult liver (Bera et al., 2001; Tammur et al., 2001;
Yabuuchi et al., 2001). These two genes have been found to be
located on human chromosome 16q12.1 in a tail-to-head orien-
tation with a separation distance of about 20 kb (Figure 1). The
predicted amino acid sequences of both gene products show a
high similarity to those of ABCC4 and ABCC5, which suggests
that they have the typical structure of “full”ABC transporters with
12 transmembrane helixes and twoABCs. Interestingly, there is no
putative mouse or rat orthologous gene corresponding to human
ABCC11 (Shimizu et al., 2003), which indicates that ABCC11 is
not an orthologous gene but rather a paralogous gene generated by
gene duplication in the human genome. In contrast, ABCC12 and
its orthologous genes are found in several different species includ-
inghumans, primates, and rodents (Shimizu et al., 2003;Ono et al.,
2007). Transcript analyses suggest that human ABCC11 mRNA is
ubiquitously expressed in human adult and fetal tissues (Tammur
et al., 2001; Yabuuchi et al., 2001). High levels of ABCC11 mRNA
were observed in breast cancer tissues (Bera et al., 2001; Yabuuchi
et al., 2001). Table 1 summarizes major ﬁndings in the research of
the ABCC11 gene.
When transfected exogenously, the ABCC11 wild-type (WT)
protein was localized in the apical membrane of Madin–Darby
canine kidney cells strain II (MDCK II cells; Bortfeld et al., 2006).
The substrate speciﬁcity of ABCC11 WT was characterized in
more detail by an in vitro transport assay with plasma mem-
brane vesicles prepared from pig LLC-PK1 cells transfected with
an ABCC11 WT expression vector (Chen et al., 2005). The results
of this assay demonstrated that ABCC11 WT is able to trans-
port a variety of lipophilic anions including cyclic nucleotides,
glutathione conjugates such as leukotriene C4 (LTC4) and S-
(2,4-dinitrophenyl)-glutathione (DNP-SG), steroid sulfates such
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FIGURE 1 | Schematic illustration of the genomic structures ofABCC11
andABCC12 genes on human chromosome 16q12.1. (A)The cytogenetic
location of the ABCC11 gene as well as the structures of exons and
introns were analyzed by BLAST searches on the human genome. A
non-synonymous SNP: 538G > A (Gly180Arg), an earwax determinant, is
located in exon 4. (B) Phylogenetic tree of the ABCC subfamily including
CFTR, SUR1, SUR2, and MRPs. The phylogenetic tree was modiﬁed from
Toyoda et al. (2008). The phylogenetic relationships among members of the
“C” sub-family of human ABC transporters were calculated by using the
distance-based neighbor-joining methods (Saitou and Nei, 1987).
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Table 1 | Historical overview on identification of theABCC11 gene and its function.
Year Scientific progress Reference
2001 Discovery of human ABCC11 (MRP8) gene Bera et al. (2001), Tammur et al. (2001),
Yabuuchi et al. (2001)
2003 Characterization of ABCC11 as a cyclic nucleotide efﬂux pump Guo et al. (2003)
2005 In vitro characterization of substrate selectivity of ABCC11 Chen et al. (2005)
2006 Characterization as an apical efﬂux pump for steroid sulfates in CNS Bortfeld et al. (2006)
2006 Identiﬁcation of ABCC11 SNP c.538G > A as the determinant of human earwax type Yoshiura et al. (2006)
2007 Association between the degrees of apocrine colostrum secretion and ABCC11 genotype Miura et al. (2007)
2008 Involvement of ABCC11 in 5-ﬂuorouracil resistance in lung cancer cell line Oguri et al. (2007)
2008 Regulation of ABCC11 expression by estrogen in MCF7 cells Honorat et al. (2008)
2009 Discovery of ubiquitination and proteasomal degradation of SNP c.538G > A variant Toyoda et al. (2009)
2009 Association between axillary osmidrosis and ABCC11 wild-type Nakano et al. (2009), Toyoda et al. (2009),
Inoue et al. (2010)
2009 Japanese map of the earwax gene frequency: a nationwide collaborative study Super Science High School Consortium (2009)
2010 Association between breast cancer risk and ABCC11 wild-type in Japanese women Ota et al. (2010), Toyoda and Ishikawa (2010)
2010 Involvement of ABCC11 in pemetrexed resistance in lung cancer Uemura et al. (2010)
2011 No association between breast cancer risk and ABCC11 wild-type in European women Beesley et al. (2011), Lang et al. (2011)
2011 Down-regulation of ABCC11 protein in human breast cancer Sosonkina et al. (2011)
as estrone 3-sulfate (E13S) and dehydroepiandrosterone 3-sulfate
(DHEAS), glucuronides such as estradiol 17-β-D-glucuronide
(E217βG), the monoanionic bile acids glycocholate and tauro-
cholate, as well as folic acid and its analog methotrexate (MTX;
Chen et al., 2005; Bortfeld et al., 2006). Chemical structures
of these compounds are presented in Figure A1 in Appendix.
While ABCC11 transports a variety of organic anions, endoge-
nous natural substrates for this transporter have not yet been
identiﬁed.
GENETIC POLYMORPHISMS AND PHYSIOLOGICAL
FUNCTION OF ABCC11
To date, more than 10 non-synonymous single-nucleotide poly-
morphisms (SNPs)havebeen reported in thehumanABCC11 gene
(Figure 2). Among those SNPs, one SNP (rs17822931; 538G > A,
Gly180Arg) determines the human earwax type (Yoshiura et al.,
2006). Interestingly, this SNP (538G > A) exhibits wide ethnic
differences in allelic frequency (Table 2). In Mongoloid popula-
tions in Asia, the frequency of the 538A allele is predominantly
high, whereas the frequency of this allele is low among Caucasians
andAfricans (Yoshiura et al., 2006; Toyoda et al., 2008; Figure 3A).
The frequency of the 538A allele exhibits a north-south and east-
west downward geographical gradient with the highest peak in
Korea. It is suggested that the 538A allele arose in northeast
Asia and thereafter spread throughout the world (Yoshiura et al.,
2006), apparently reﬂecting the inter-continental migration of
Homo sapiens (Figure 3B). A similar geographical gradient was
also observed in the frequency of the 2677G (Ala893) allele of the
ABCB1 (P-glycoprotein/MDR1) gene (Sakurai et al., 2007). In this
regard, anthropological aspects of SNP 538G > A in the ABCC11
gene are described in the following section.
FIGURE 2 | Schematic illustration of ABCC11 protein structure and
hitherto known non-synonymous SNPs. ABCC11 has a total of 12
transmembrane (TM) regions and two intracellular ATP-binding cassettes.
Asn838 and Asn844 residing in an extracellular loop between
transmembrane helicesTM7 andTM8 are N -linked glycosylation sites in the
ABCC11WT protein. Locations of hitherto reported non-synonymous SNPs
and Δ27 (a rare deletion mutation) are indicated in the putative structure of
ABCC11. G180R and Δ27 are related to the formation of dry-type earwax.
Earwax (cerumen) is a secretory product of the ceruminous
apocrine glands, which can be classiﬁed into two phenotypes in
humans, wet (sticky) and dry. The dry-type is most commonly
found within the Asian population, especially among Koreans,
Japanese, and Chinese; whereas the wet-type is the dominant phe-
notype for many Africans and Caucasians. The 538A/A genotype
gives the dry phenotype, whereas both the 538G/A and G/G geno-
types give the wet phenotype. This relationship is consistent with
observations that earwax type is a Mendelian trait and that the wet
phenotype is dominant to the dry one.
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Table 2 | Frequencies ofABCC11 genotypes and allele c.538A among different ethnic groups.
Ethnic groups Tribes or inhabitants No. of individuals with genotypes Number of
individuals
genotyped
Frequency
of allele
“A”AA (frequency) GA GG
Korean§ Daegu city inhabitants 100 (1.000) 0 0 100 1.000
Chinese§ Northern and southern Han Chinese 42 (0.808) 10 0 52 0.904
Mongolian Khalkha tribe§ 126 (0.759) 36 4 166 0.867
Japanese Nagasaki people (West-end prefecture of Japan mainland)§ 87 (0.690) 35* 4 126 0.829
Okinawa people (Southwest-end prefecture of Japan) 30 (0.517) 25 3 58 0.733
Yonaguni islander (West-end island of Japan)§ 13 (0.433) 15 2 30 0.683
Ainu in Biratori-Nibutani village in Hokkaido§ 31 (0.534) 23 2 58 0.733
Vietnamese People from multiple regions 82 (0.536) 60 11 153 0.732
Thai Northern Thai [Lahu, Shan, Lisu, Hmong, Akha, Mlaburi,
and Karen (Mae-sot Thai) tribes combined]
215 (0.505) 163 48 426 0.696
Central Thai in Bangkok 31 (0.633) 10 8 49 0.735
Southern Thai (Orang Laut and Sakai tribes combined) 2 (0.026) 23 52 77 0.175
Indonesian Dayak tribe in Kalimantan 12 (0.293) 23 9 41 0.573
Toraja and Bugis tribes in Sulawesi 27 (0.270) 49 24 100 0.515
Flores 18 (0.300) 25 17 60 0.508
Sumba 9 (0.180) 16 25 50 0.340
WA tribe in Irian Jaya 0 (0.000) 2 31 33 0.030
Malaysian Sabah in North Borneo§ 24 (0.393) 27 10 61 0.566
Bentong tribe 8 (0.113) 40 23 71 0.394
Taiwanese Taiwan Aborigine (Yami and Ami combined) 34 (0.330) 48 21 103 0.563
Native American§ 6† (0.300) 8† 6 20 0.500
Filipino Palawan 11 (0.229) 23 14 48 0.469
Easter Islander§ 4 (0.148) 17 6 27 0.463
Paciﬁc islander§ 1 (0.143) 1 5 7 0.429
Bolivian§¶ Aymara 5 (0.167) 14 11 30 0.400
Kazakh 6 (0.200) 11 13 30 0.383
Native Paraguayan Ayoreos 2 (0.040) 34 14 50 0.380
Sanapana 0 (0.000) 14 61 75 0.093
Russian§ 5 (0.045) 45 62 112 0.246
Solomon Islander§ 2 (0.323) 25 35 62 0.234
French§ From the CEPH families 1 (0.083) 3 8 12 0.208
Andes people§ 1 (0.100) 2† 6 10 0.200
Hungarian§ 0 (0.000) 4 6 10 0.200
Jew§ Ashkenazi 0 (0.000) 4 6 10 0.200
Ukrainian§ 0 (0.000) 15 27 42 0.179
Papuan Papua New Guinea 1 (0.026) 11 26 38 0.171
American of European From CEPH families without the French and Venezuelans 1 (0.012) 16 65 82 0.110
ancestry§
Venezuelan§ Ye’Kuana village 0 (0.000) 3 11 14 0.107
Sanuma village 0 (0.000) 0 19 19 0.000
Vanuatu islander Aneityum and Santo islanders combined 1 (0.011) 17 74 92 0.103
Iberian§ 0 (0.000) 2 8 10 0.100
Columbian 0 (0.000) 2 17 19 0.053
African From various sub-Saharan nations 0 (0.000) 1 11 12 0.042
American of African
ancestry§
0 (0.000) 0 10 10 0.000
Data are fromYoshiura et al. (2006). §Examined for a 27-bp deletion (A27) in ABCC11; *One exceptional case of dry cerumen who has the deletion; †One each case
of the deletion; ¶Nine cases of the deletion.
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FIGURE 3 |The allele frequencies of the wild-type (WT; Gly180) and
538G >A (Arg180) variant of humanABCC11 among different ethnic
populations (A) and inter-continental migration of Homo sapiens (B).
Data are fromYoshiura et al. (2006) andToyoda et al. (2008).
Immunohistochemical studies with cerumen gland-containing
tissue specimens revealed that the ABCC11 WT protein with
Gly180 was expressed in the cerumen gland (Toyoda et al., 2009).
The cerumen gland is one of the apocrine glands. In addition
to their presence in the external auditory canal, apocrine glands
can be found in the axillary region and breast, whose physical
characteristics also are concerned with apocrine glands. In fact,
there is a positive association among the wet earwax type, axillary
osmidrosis (Yoo et al., 2006), and colostrum secretion from the
breast (Miura et al., 2007).
ANTHROPOLOGICAL ASPECTS OF ALLELES 538G AND 538A
It is generally accepted that, since they migrated out-of-Africa,
humans spread all over the world with great diversity (Cavalli-
Sforza, 2005). Whilst the routes of migration followed by the
ancient Mongoloid people remain obscure, two different routes
have been proposed (Figure 3B). After branching from a main
stream common to the ancient Caucasoids 150,000–60,000 years
ago (Nei, 1982), the ancient Mongoloids migrated to Southern
Asia. It is assumed that one branch remained there or further
migrated more south-eastwardly through the so-called Sunda-
land and Sahuland, and ﬁnally reached the Australian continent
50,000–46,000 years ago (Bowler et al., 2003). The last wave of
migration of people to the Southern Paciﬁc islands took place
more recently, 3,000–1,500 years ago. On the other hand, another
branchmigratednorthward and reached an area aroundLakeBikal
of Siberia along the Altai mountains. Alternatively, a branch of the
ancient Mongoloids might have directly migrated to Siberia from
the common stream or migrated from South East Asia toward
North East Asia (The HUGO Pan-Asian SNP Consortium, 2009).
As an expansionof the last glaciationoccurred 30,000–15,000 years
ago, small tribes of the ancient Northern Mongoloids may have
long been isolated by the glaciers.
As described above, wet/dry types of earwax are determined
by the SNP c.538G > A in the ABCC11 gene; G/A and G/G geno-
types give the wet-type andA/A the dry-type. There is a hypothesis
that a c.538G (wet-type) → c.538A (dry-type) mutation may have
occurred some 40,000 years ago in a tribe of the ancient North-
ern Mongoloids (Ohashi et al., 2011). Subsequent spreading of the
dry-type among the Mongoloids may be explained by a certain
selective advantage of the mutation (Matsunaga, 1962), or dry
cerumen might have been evolutionally neutral, which would have
led to its spread as an attribute of genetic drift. Based on the geo-
graphical gradient distribution of the 538A allele with a peak in
East Asia, especially in Northern China and Korea, one might
assume that the c.538G → c.538A mutation arose somewhere in
Siberia. The north-south downward gradient of the 538G allele
from Northern China toward Japan and Southern Asia might
reﬂect the Ancient Northern Mongoloid migrations. Similarly,
the east-west gradient from Siberia toward Europe (Spitsyn and
Afanasèva, 1989) is partly the consequence of Mongolian migra-
tion, especially as their invasions pushed westward from about
A.D. 500 until A.D. 1500. The situation is much like the fre-
quency of type B for the ABO blood group, which is high in
Asia (>25%) and low (<10%) in Europe (Roychoudhury and
Nei, 1988). Similar geographic distribution and ethnic differences
are known for the ALDH2 gene, one of the major determinants
for alcohol sensitivity (Goedde et al., 1992; Luo et al., 2009).
The relatively high frequency of the 538A allele among present-
day Native Americans suggests that their ancestors may have
undertaken long journeys from Siberia through the Bering land-
bridge (Beringia) to the American continent during the past
15,000 years (Horai et al., 1993; Bonatto and Salzano, 1997; Toku-
naga et al., 2001; Dillehay, 2003). Based on recent craniometric
studies of skeletons from archeological remains in the Baja Cal-
ifornia peninsula, however, it has also been postulated that an
earlier migration wave from that via the northern route might
have occurred from islands of south-eastern Asia by an ancestor
common tobothPalaeoamericans andAustralians around40,000–
12,000 years ago (Gonzáles-José et al., 2003). Furthermore, the
allelic data for SouthAmericans revealing the 538Aallele frequency
of 0.400 in Bolivia, 0.200 in the Andes region, 0.093–0.380 in
Paraguay, 0.053 in Colombia, and 0.000 in Venezuela rather favors
a hypothesis of an ancientmigration through a“paciﬁc coast road”
along the Andes mountain range.
ROUTES OF THE JAPANESE POPULATION
The Japanese population is considered to have a dual struc-
ture comprising descendants of mixtures between the ancient
“Jomon” and “Yayoi” populations. The term “Jomon” is derived
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from characteristic twisted cord striations or marks on earthen-
ware used during a prehistoric time (13,000–3,000 years ago) in
Japan. As it has been reported that the Jomonhadoccupied various
areas of Japan prior to theYayoi’s appearance, they apparently were
either assimilated or rather moved away from the Yayoi (Iizuka
and Nakahashi, 2002; Temple et al., 2008; Temple, 2010). It is
hypothesized that the dry earwax type was introduced by theYayoi
people to the Jomon population, where the wet-type had been
predominant.
Since the admixture of the two Jomon andYayoi populations is
still not complete in Japan even now, the 538G allele frequency
is higher in the rather remote areas where the Jomon moved
away from the Yayoi’s peopling route within the Japanese islands.
The Ainu-Japanese people living in a Japanese northern island
“Hokkaido” are aboriginal inhabitants of Japan. Based on mor-
phological and mitochondrial DNA polymorphism studies, it has
been hypothesized that both the Ainu- and the Okinawa-Japanese
living in a Japanese southern island “Okinawa” are descendants of
the ancient native Japanese, “Jomon” people (Horai et al., 1991).
Molecular studies demonstrated that Ainu-Japanese still retain a
certain degree of their own genetic uniqueness among surround-
ing populations, and exhibit considerable genetic distance from
other East Asian populations (Tokunaga et al., 2001; Tajima et al.,
2004). As far as wet-type of earwax and the 538G allele frequency
are concerned, theAinu- andOkinawa-Japanese people are not the
direct descendants“Yayoi”from theAncientNorthernMongoloids
of Siberian origin.
To analyze the nationwide allele frequency, the Super Science
High School (SSH) consortium collected a total of 1963 ﬁngernail
samples of pupils/students fromat least one high school/university
in every prefecture in Japan (Super Science High School Consor-
tium, 2009). Although the 538G allele frequency varied among the
47 prefectures, the Gifu/Kyoto and Okinawa prefectures showed
the lowest and highest values for the 538G allele, respectively.
Other areas with low frequencies of the 538G allele included
Northeastern Kyushu, Northern Shikoku, and Kinki districts,
showing a belt-like zone, whereas those with high frequencies of
the 538G allele next to Okinawa were the Southwestern Kyushu,
Hiroshima prefecture, and Tohoku districts. Those observations
strongly suggest that the admixture of “Jomon” and “Yayoi”
populations is still not complete in Japan.
STRONG ASSOCIATION BETWEEN AXILLARY OSMIDROSIS
AND THE GENOTYPE OF ABCC11 538G> A
Today in Japan, axillary osmidrosis is recognized as a disease that is
covered by the national health insurance system. Axillary osmidro-
sis, which is exempliﬁed by unpleasant odors, sweating and
staining of clothes, is often perceived, especially by young women,
as a distressing and troublesome problem (Wu et al., 1994). Axil-
lary osmidrosis is a chronic skin condition characterized by an
excessive, axillary malodor resulting from apocrine gland dysfunc-
tion (Hess et al., 2008). Certain people display an excessive fear,
aversion or psychological hypersensitivity to unpleasant smells or
odors. They tend to opt for aggressive surgical treatments and are
sometimes categorized as having osmophobia. Interestingly, an
association between wet-type earwax and axillary osmidrosis had
already been recognized more than half a century ago (Matsunaga,
Table 3 | Association ofABCC11 genotype with earwax type and
axillary osmidrosis in Japanese subjects.
Earwax type Genotype atABCC11 538G >A Axillary osmidrosis
patients
G/G G/A A/A
Dry 262 0 0 262 0
Wet 300 23 277 0 182
Data are calculated from Inoue et al. (2010) and Nakano et al. (2009).
1962). Hence, the wet-type of earwax has frequently been used as
one of diagnostic criteria and characteristics in the clinic. This
relationship, however, had only been based on the observations
of those two respective phenotypes. Therefore, there has been a
need for objective evidence for diagnosis of axillary osmidrosis to
prevent unnecessary treatments for such patients.
Recently, it has been reported that the ABCC11 WT allele
is intimately associated with axillary osmidrosis as well as the
wet-type of earwax (Table 3). Several studies have already con-
cluded that the genotypes at ABCC11 538G > A would be useful
biomarkers for the diagnosis of axillary osmidrosis (Nakano et al.,
2009; Toyoda et al., 2009; Inoue et al., 2010; Martin et al., 2010).
Therefore, it is suggested that genotyping of the ABCC11 gene
would provide an accurate and practical criterion for guidance of
appropriate treatment and psychological management of patients
(Toyoda et al., 2009; Inoue et al., 2010; Ishikawa and Hayashizaki,
2012). Rapid genotypingof theABCC11 gene is brieﬂydescribed in
Appendix.
Sweat produced by the axillary apocrine glands is odorless.
Secretions from the apocrine glands, however, can be converted
to odoriferous compounds by bacteria (Corynebacteria), which
results in the formation of the unique“human axillary odor”(She-
hadeh and Kligman, 1963). Axillary osmidrosis patients (538G/G
homozygote or G/A heterozygote) were observed to have signif-
icantly more numerous and larger-sized axillary apocrine glands
as compared with those in subjects carrying the A/A homozygote.
Indeed, the 538G allele in the ABCC11 gene is associated with
axillary osmidrosis (Nakano et al., 2009; Toyoda et al., 2009; Inoue
et al., 2010; Martin et al., 2010), and ABCC11 WT (Gly180) would
be responsible for the secretion of preodoriferous compounds
from the axillary apocrine gland. In primates, axillary odors may
play a role in olfactory communication, although no documented
behavioral or endocrine changes resulting from volatiles produced
in the axillae have been reported to occur in humans. Previous
studies have described the presence of androgen steroids in the
axillary area. Androsterone sulfate (AS) and DHEAS were detected
in an extract of axillary hairs in addition to high levels of choles-
terol (Julesz, 1968). It was also demonstrated, following injection
of radioactive pregnenolone or progesterone, that steroid secretion
was concentrated in the axillary area (Brooksbank, 1970). In those
studies, however, the axillary sweat collected from the skin sur-
face contained a mixture of materials from apocrine, eccrine, and
sebaceous glands, in addition to desquamating epidermal cells. In
this respect, Labows et al. (1979) demonstrated that pure apoc-
rine secretions contained at least two androgen steroids, AS and
DHEAS, in addition to cholesterol. It is strongly suggested that
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one of the physiological functions of ABCC11 WT is the active
transport of steroid metabolites, such as AS and DHEAS, into the
lumen of apocrine glands.
ENDOPLASMIC RETICULUM-ASSOCIATED DEGRADATION OF
THE SNP VARIANT OF ABCC11
Why does one SNP (c.538G > A) in the human ABCC11 gene
affect the function of apocrine glands? To address this question, we
have recently provided evidence that proteasomal degradation of
the SNP variant (Arg180) of ABCC11 is the underlying molecular
mechanism (Toyoda et al., 2009). ABCC11 WT with Gly180 is
an N-linked glycosylated protein, which is localized within intra-
cellular granules and large vacuoles as well as at the luminal
membrane of secretory cells in the cerumen apocrine gland (Toy-
oda et al., 2009). N-linked glycosylation occurs at bothAsn838 and
Asn844 in the extracellular loop between transmembrane domains
7 (TM7) and 8 (TM8) of the ABCC11 WT protein. In contrast,
the SNP variant (Arg180) lacks N-linked glycosylation and readily
undergoes proteasomal degradation, most probably via ubiquiti-
nation. As a consequence, no granular or vacuolar localization was
detected in the cerumen apocrine glands of people homozygous
for the SNP variant.
Morphological differences were previously reported between
the secretory cells of wet and dry types of human ceruminous
glands (Shugyo et al., 1988). In the wet-type glands, the Golgi
apparatus was reportedly well developed, whereas it was generally
small in the corresponding cells of the dry-type. Furthermore,
numerous intracellular granules were observed in the wet-type
gland in close relationship to theirwell-developedGolgi apparatus,
whereas intracellular granules were rare in the dry-type gland.
The endoplasmic reticulum (ER) and Golgi apparatus are the
synthesis and maturation sites of proteins destined for the plasma
membrane, the secretory and endocytic organelles, and secretion
(Ellgaard et al., 1999; Helenius and Aebi, 2004). Efﬁcient quality
control systems have evolved to prevent incompletely folded pro-
teins from moving along the secretory pathway. Accumulation of
misfolded proteins in the ER would detrimentally affect cellular
functions. Therefore,misfolded proteinsmay be removed from the
ER by retrotranslocation to the cytosol compartment where they
are degraded by the ubiquitin-proteasome system. This process
is known as ER-associated degradation (ERAD; Mori, 2000; Ell-
gaard andHelenius, 2001; Hampton, 2002; Kleizen and Braakman,
2004). It is likely that the product of the SNP variant (Arg180) is
recognized as a misfolded protein in the ER and readily undergoes
proteasomal degradation. An electrostatic charge (either positive
or negative) at amino acid 180 in the transmembrane domain 1
(TM1) might interfere with correct folding of the de novo syn-
thesized ABCC11 protein in the ER (Toyoda et al., 2009). This
ERAD processing of the SNP variant (Arg180) of ABCC11 may
greatly inﬂuence the activity of ceruminous apocrine glands and
determine the type of human earwax. Similar ERAD processing is
considered to take place for the SNP variant (Arg180) of ABCC11
in axillary and mammary apocrine glands. Figure 4 schemati-
cally illustrates the impact of this SNP on the cellular localization
and function of ABCC11 in secretory cells of the apocrine gland.
Asn838 and Asn844 are glycosylation target sites in the human
ABCC11. The N-linked glycans are thought to be subjected to
extensive modiﬁcation as glycoproteins mature and move through
the ER via the Golgi apparatus to their ﬁnal destinations as, for
example, intracellular granules and large vacuoles of secretory cells
in the apocrine gland.
ABCC11 WILD-TYPE ALLELE AND BREAST CANCER RISK
In 1971, Petrakis (1971) ﬁrst reported that international mortal-
ity and frequency rates for breast cancer seemed to be associated
with the frequency of the allele for wet-type earwax. Caucasians
and African–Americans in the USA as well as Germans exhibited
approximately fourfold higher rates of breast cancer mortality as
compared with Japanese and Taiwanese women (Petrakis, 1971).
Nevertheless, the phenotypic association of the wet-type of ear-
wax with breast cancer remained controversial (Petrakis, 1971; Ing
et al., 1973).
At the present time, it is not well understood whether ABCC11
WT really contributes to breast cancer risk. Therefore, we have
most recently carried out a genotyping study of the SNP 538G>A
(Gly180Arg) for a total of 543 Japanese women to examine the
association between the frequency rate of breast cancer and the
allelic frequency of the G allele (WT). We obtained blood samples
from patients with invasive breast cancer (n = 270) and control
volunteers (n = 273) and genotyped the SNP c.538G > A in the
ABCC11 gene. The frequency of the 538Gallele in the breast cancer
patients was higher than that in the control volunteers. The odds
ratio for the women with genotypes (G/G + G/A) to develop
breast cancer was estimated as 1.63 (p-value = 0.026), suggesting
that the 538G allele in the ABCC11 gene is moderately associated
with the risk of breast cancer (Ota et al., 2010). The relative ratio of
breast cancer patients carrying the homozygous 538G/G allele was
1.77-fold greater than that of the corresponding healthy volunteers
(Ota et al., 2010). This relative ratio was even greater than that
(1.41-fold) for breast cancer patients carrying heterozygous alleles
538G/A. The G allele appears to be positively related to breast
cancer frequency in the groups of Japanese women studied. In
contrast, no signiﬁcant association with breast cancer risk was
observed in Europeans (Beesley et al., 2011; Lang et al., 2011).
We initially thought that some genetically determined varia-
tion(s) in the apocrine system might inﬂuence susceptibility to
breast cancer, although the genetic determinant (538G > A SNP
in ABCC11) was not known at that time. It is hypothesized that
the function of ABCC11 per se, or metabolites transported by
ABCC11, may stimulate the proliferation of apocrine gland cells
to enhance the risk of mastopathy (Figure 5). This hypothesis is
supported by evidence that apocrine glands are large in individu-
als carrying the WT allele of the ABCC11 gene. So far as the cell
cycle machinery is operating normally, proliferation of apocrine
gland cells should be controlled to a certain extent.When a somatic
mutation has occurred in BRCA1, BRCA2, p53, or p21, however, it
can lead to deleterious and unregulated proliferation of those cells
(Figure 5).
REGULATION OF ABCC11 GENE EXPRESSION
In 2004, Bieche et al. (2004) reported that ABCC11 was up-
regulated in estrogen receptor α-positive breast tumors, as com-
pared with normal breast tissue. In contrast, Sosonkina et al.
(2011) reported down-regulation of ABCC11 protein in human
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FIGURE 4 | Schematic illustration of intracellular sorting of ABCC11
WT and proteasomal degradation of the R180 (Arg180) variant in
secretory cells of the apocrine gland. De novo synthesized ABCC11WT
is N -linked glycosylated at Asn838 and Asn844 in the ER, further processed in
the Golgi apparatus, and destined for the membranes of intracellular granules
and vacuoles. Ceruminous components are thought to be transported by
ABCC11WT and sequestered in intracellular granules and vacuoles.
SNP variant R180 lacking N -linked glycosylation is recognized as a
misfolded protein in the ER and readily undergoes ubiquitination and
proteasomal degradation (ERAD pathway). ER, endoplasmic reticulum;
ERAD, ER-associated degradation. This scheme is modiﬁed from
Toyoda et al. (2009).
FIGURE 5 |The potential impact ofABCC11WT (538G) on the apocrine
phenotype, patients’ response to nucleoside-based chemotherapy, and
the potential risk of mastopathy and breast cancer. BRCA-1, breast
cancer-1; BRCA-2, breast cancer-2; PI3K, phosphatidylinositol 3-kinase; ERα
(+), estrogen receptor α-positive; 5-FU, 5-ﬂuorouracil; AraC, cytarabine. This
scheme is modiﬁed formToyoda and Ishikawa (2010).
breast cancer. Park et al. (2006) investigated the mRNA levels
of ABC transporter genes in breast cancer patients who under-
went sequential weekly paclitaxel/FEC (5-ﬂuorouracil, epirubicin,
and cyclophosphamide) neoadjuvant chemotherapy. Their anal-
ysis showed that the expression of ABCC11 was increased (fold
ratio = 2.71) in those patients with residual disease as compared
with the patients having no pathologic evidence of any residual
invasive cancer cells in the breast.
Honorat et al. (2008) have demonstrated that endogenous
ABCC11 mRNA levels in breast cell lines are correlated with their
estrogen receptor α-status. Interestingly, they found that ABCC11
expression was reduced in vitro by E2 treatments. Furthermore,
this E2-dependent down-regulation of ABCC11 expression was
blocked by co-treatment with tamoxifen, an E2 antagonist. These
ﬁndings suggest that ABCC11 expression is regulated directly or
indirectly by estrogen receptor α and that the prolonged exposure
of breast cancer cells to tamoxifen can lead to up-regulation of
ABCC11.
Hauswald et al. (2009) have shown that some of the histone
deacetylase inhibitors induced the expression of several ABC
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transporters, including the ABCC11 gene, to render acute myeloid
leukemia cells resistant to a broad-spectrum of drugs. Molecu-
lar mechanisms underlying the induction remain to be elucidated.
Since histone deacetylase inhibitors can be utilized in combination
with conventional anti-cancer drugs in clinical trials, such induc-
tionof theABCC11WTmay affect the efﬁcacy of nucleoside-based
chemotherapy.
RELEVANCE OF ABCC11 WT TO DRUG RESISTANCE IN
CANCER CHEMOTHERAPY
The potential involvement of ABCC11 in drug resistance of
breast cancer has recently been reported. For example, ABCC11
mRNA is found to be highly expressed in breast tumors (Bera
et al., 2001; Yabuuchi et al., 2001; Bieche et al., 2004), and
particularly in invasive ductal adenocarcinomas (available at:
https://www.oncomine.org/resource/logn.html, accessed October
01, 2012). This expression is reportedly regulated by estrogen
receptor-β (Honorat et al., 2008) and induced by 5-ﬂuorouracil
(5-FU; Oguri et al., 2007). Furthermore, it has been shown that
ABCC11 is directly involved in 5-FU resistance by means of the
efﬂux transport of the active metabolite 5-ﬂuoro-2′-deoxyuridine
5′-monophosphate (FdUMP; Guo et al., 2003; Kruh et al., 2007;
Oguri et al., 2007). It remains to be elucidated whether the expres-
sion of ABCC11 WT (538G) is related to drug resistance of
breast cancer and high rates of mortality. Further clinical studies,
including protein expression studies in tumors, will be needed
to clarify the potential contribution of ABCC11 to breast can-
cer risk and prognosis, including drug resistance and chemosen-
sitivity.
Because of their structural similarities, it could be anticipated
that substrate speciﬁcity of ABCC11 would be related to those
of ABCC4 and ABCC5. This indeed has been the case. Ectopic
expression of ABCC11 in mammalian cells enhances the cellu-
lar efﬂux of cyclic nucleotides and confers resistance to certain
anticancer and antiviral nucleotide analogs (Guo et al., 2003). In
fact, it has been reported that ABCC11 WT has an ability to efﬂux
cyclic nucleotides (e.g., cGMP and cAMP) and confers resistance
to several antiviral and anticancer nucleotide analogs, such as 5′-
FdUMP and 9′-(2′-phosohonylmethoxynyl)adenine (PMEA; Guo
et al., 2003; Kruh et al., 2007; Oguri et al., 2007).
Therapy with nucleoside-derived drugs is characterized by
inter-individual variability (Heinemann et al., 1988; Abbruzzese
et al., 1991). Genetic variants that affect protein products involved
in all steps leading to a drug’s action may be major contributors
to this heterogeneity of responses to nucleoside-based treat-
ments. In particular, variants of drug metabolizing enzymes and
transporters might affect the amount of drug needed for an
efﬁcient therapeutic response (Errasti-Murugarren and Pastor-
Anglada, 2010).
Successful treatment of cancer remains a therapeutic challenge,
with a high percentage of patients suffering from drug resistance
or relapsed disease. One of such examples involves anti-leukemia
treatment with nucleoside analogs, such as cytarabine (AraC).
Guo et al. (2009) have recently presented evidence that expression
of ABCC11 WT is an important factor affecting acute myeloid
leukemia patient survival. It is very likely that the cause of treat-
ment failure in those patients with high expression of ABCC11
WT is an increased extrusion of AraC from blast cells mediated by
the transporter.
Uemura et al. (2010) have recently found that both gene and
protein expression of ABCC11 were higher in pemetrexed (MTA)-
resistant cells than in the parental cells. The MTA-resistant cells
showed cross-resistance to MTX,which is a substrate for ABCC11,
and intracellular MTX accumulation in MTA-resistant cells was
lower than that in the parental cells. They then tested the effect
of decreasing the expression of ABCC11 by siRNA and found that
decreased expression of ABCC11 enhanced MTA cytotoxicity and
increased intracellular MTX accumulation in MTA-resistant cells.
These ﬁndings suggest that ABCC11 confers resistance to MTA by
enhancing the efﬂux of the intracellular anti-cancer drug.
They further analyzed the relationship between the ABCC11
gene expression and MTA sensitivity of 13 adenocarcinoma cell
lines. In contrast to their expectation, there was no correlation.
Instead, the 13 lung adenocarcinoma cell lines could be classiﬁed
into three groups based on the genotypes of the ABCC11 SNP
(538G > A); G/G, G/A, and A/A. The A/A group showed a sig-
niﬁcant reduction in the IC50 value of MTA compared with those
values for the combined G/G and G/A groups, indicating that
ABCC11 538G> A is an important determinant of MTA sensitiv-
ity. These results suggest thatABCC11 538G>A may be one of the
biomarkers for selection of MTA treatment in adenocarcinomas.
This ﬁnding, however, should be carefully evaluated by clinical
studies to determine whether ABCC11 538G > A is truly a clini-
cally important biomarker for the prediction of chemotherapeutic
efﬁcacy.
CONCLUSION
Apocrine secretion occurs when the secretory process is accom-
plishedwith a partial loss of cell cytoplasm. The secretorymaterials
may be contained within the secretory vesicles or dissolved in the
cytoplasm and then released during excretion as cytoplasmic frag-
ments into the glandular lumen or interstitial space (Gesase and
Satoh, 2003). Hitherto, apocrine secretory mechanisms have not
been well characterized (Gesase and Satoh, 2003). Although the
biochemical and physiological pathways that regulate the apoc-
rine secretory process are not clearly known, our recent ﬁndings
(Yoshiura et al., 2006; Toyoda et al., 2009; Inoue et al., 2010) that
the SNP (538G > A, Gly180Arg) in the ABCC11 gene determines
both earwax type and axillary osmidrosis have shed light on the
novel function of thisABC transporter in apocrine glands. Further
studies are needed to explore the clinical signiﬁcance of ABCC11
so as to elucidate whether there are any other diseases that involve
apocrine secretion.
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APPENDIX
CLINICAL GENOTYPING OF SNP 538G> A (Gly180Arg) IN THE ABCC11 GENE
The rapid growth of personalized medicine is being supported by emerging new technologies together with accumulating knowledge
of pharmacogenomics. We tried to create a clinical method, the SmartAmp, to genotype the SNP 538G > A in the human ABCC11
gene. The SmartAmp-based method enables us to detect genetic polymorphisms or mutations in about 30 min under isothermal
conditions without requiring DNA isolation and PCR processes for sample preparation (Ishikawa and Hayashizaki, 2012). Figure A2A
schematically illustrates the strategy of SNP detection by this clinical method. To determine the SNP 538G > A (Gly180Arg) in the
ABCC11 gene, we prepared one set of primers designated TP, FP, BP,OP, and CP (FigureA2A). The TPS discriminate the polymorphism
538G or 538A in the ABCC11 gene, and the CPS inhibit the background ampliﬁcation from mismatch sequence pairs (Toyoda et al.,
2009; Ishikawa and Hayashizaki, 2012). These primers selectively recognized the SNP 538G > A of the ABCC11 gene to discriminate
homozygous 538G/G, heterozygous 538G/A, and homozygous 538A/A (Figure A2A). Thus, this genotyping method would provide a
practical tool to support clinical diagnosis (Ishikawa and Hayashizaki, 2012).
FIGUREA1 | Chemical structures of ABCC11 substrates. Cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), leukotriene
C4 (LTC4), S-(2,4-dinitrophenyl)-glutathione (DNP-SG), estrone 3-sulfate (E13S), dehydroepiandrosterone 3-sulfate (DHEAS), and E217βG (estradiol 17-β-D-
glucuronide).
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FIGUREA2 | Detection of SNP 538G >A inABCC11 gene. (A) Strategy
and primers for the SmartAmp-based detection of SNP 538G > A residing
in exon 4 of the ABCC11 gene on chromosome 16q12 (upper panel) and
the sequences of ABCC11 allele–speciﬁc primers needed for the SNP
detection (lower panel). Arrows indicated the sequence difference
between theWT and SNP alleles. (B)Time-courses of the SNP-
detection reaction with ABCC11 allele-speciﬁc primers. Data are from
Toyoda et al. (2009).
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